{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:18:21Z","timestamp":1707524301490},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,4]]},"DOI":"10.7759\/cureus.16177","type":"journal-article","created":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T22:15:30Z","timestamp":1625436930000},"source":"Crossref","is-referenced-by-count":1,"title":["Long-Term Survival With Pembrolizumab Re-administration After Pseudo-Progression With Immune-Related Interstitial Lung Disease in a Patient With Non-small Cell Lung Cancer"],"prefix":"10.7759","author":[{"given":"Koki","family":"Nakashima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiki","family":"Demura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaya","family":"Akai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamotsu","family":"Ishizuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-008-0642-y","article-title":"Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases","volume":"58","author":"Di Giacomo AM","year":"2009","unstructured":"Di Giacomo AM, Danielli R, Guidoboni M, et al.. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother. 2009, 58:1297-306. 10.1007\/s00262-008-0642-y","journal-title":"Cancer Immunol Immunother"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok JD","year":"2009","unstructured":"Wolchok JD, Hoos A, O'Day S, et al.. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009, 15:7412-20. 10.1158\/1078-0432.CCR-09-1624","journal-title":"Clin Cancer Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE- 042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok TS","year":"2019","unstructured":"Mok TS, Wu YL, Kudaba I, et al.. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE- 042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019, 393:1819-30. 10.1016\/S0140-6736(18)32409-7","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","volume":"383","author":"Herbst RS","year":"2020","unstructured":"Herbst RS, Giaccone G, de Marinis F, et al.. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med. 2020, 383:1328-39. 10.1056\/NEJMoa1917346","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.12877","article-title":"Pleural or pericardial metastasis: a significant factor affecting efficacy and adverse events in lung cancer patients treated with PD-1\/PD-L1 inhibitors","volume":"9","author":"Kang DH","year":"2018","unstructured":"Kang DH, Chung C, Kim JO, et al.. Pleural or pericardial metastasis: a significant factor affecting efficacy and adverse events in lung cancer patients treated with PD-1\/PD-L1 inhibitors. Thorac Cancer. 2018, 9:1500-8. 10.1111\/1759-7714.12877","journal-title":"Thorac Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.12894","article-title":"Hyperprogressive disease in patients with non-small cell lung cancer treated with nivolumab: a case series","volume":"9","author":"Kanazu M","year":"2018","unstructured":"Kanazu M, Edahiro R, Krebe H, et al.. Hyperprogressive disease in patients with non-small cell lung cancer treated with nivolumab: a case series. Thorac Cancer. 2018, 9:1782-7. 10.1111\/1759-7714.12894","journal-title":"Thorac Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13180","article-title":"Baseline tumor size as a predictive and prognostic factor of immune checkpoint inhibitor therapy for non-small cell lung cancer","volume":"39","author":"Katsurada M","year":"2019","unstructured":"Katsurada M, Nagano T, Tachihara M, et al.. Baseline tumor size as a predictive and prognostic factor of immune checkpoint inhibitor therapy for non-small cell lung cancer. Anticancer Res. 2019, 39:815-25. 10.21873\/anticanres.13180","journal-title":"Anticancer Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2019.10.002","article-title":"Baseline tumor size and survival outcomes in lung cancer patients treated with immune checkpoint inhibitors","volume":"46","author":"Hopkins AM","year":"2019","unstructured":"Hopkins AM, Kichenadasse G, McKinnon RA, Rowland A, Sorich MJ. Baseline tumor size and survival outcomes in lung cancer patients treated with immune checkpoint inhibitors. Semin Oncol. 2019, 46:380-4. 10.1053\/j.seminoncol.2019.10.002","journal-title":"Semin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"378","author":"Forde PM","year":"2018","unstructured":"Forde PM, Chaft JE, Smith KN, et al.. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. 2018, 378:1976-86. 10.1056\/NEJMoa1716078","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer","volume":"36","author":"Arbour KC","year":"2018","unstructured":"Arbour KC, Mezquita L, Long N, et al.. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol. 2018, 36:2872-8. 10.1200\/JCO.2018.79.0006","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13483","article-title":"Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: case series and literature review","volume":"11","author":"Kitagawa S","year":"2020","unstructured":"Kitagawa S, Hakozaki T, Kitadai R, Hosomi Y. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: case series and literature review. Thorac Cancer. 2020, 11:1927-33. 10.1111\/1759-7714.13483","journal-title":"Thorac Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyz066","article-title":"The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer","volume":"49","author":"Watanabe H","year":"2019","unstructured":"Watanabe H, Kubo T, Ninomiya K, et al.. The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer. Jpn J Clin Oncol. 2019, 49:762-5. 10.1093\/jjco\/hyz066","journal-title":"Jpn J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer","volume":"6","author":"Dolladille C","year":"2020","unstructured":"Dolladille C, Ederhy S, Sassier M, et al.. Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol. 2020, 6:865-71. 10.1001\/jamaoncol.2020.0726","journal-title":"JAMA Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1776058","article-title":"Impact of pseudoprogression and treatment beyond progression on outcome in patients with non-small cell lung cancer treated with immune checkpoint inhibitors","volume":"9","author":"Won SE","year":"2020","unstructured":"Won SE, Park HJ, Byun S, et al.. Impact of pseudoprogression and treatment beyond progression on outcome in patients with non-small cell lung cancer treated with immune checkpoint inhibitors. Oncoimmunology. 2020, 9:1776058. 10.1080\/2162402X.2020.1776058","journal-title":"Oncoimmunology"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.08.022","article-title":"Early immune-related adverse events and association with outcome in advanced non-small cell lung cancer patients treated with nivolumab: a\u00a0prospective cohort study","volume":"12","author":"Teraoka S","year":"2017","unstructured":"Teraoka S, Fujimoto D, Morimoto T, et al.. Early immune-related adverse events and association with outcome in advanced non-small cell lung cancer patients treated with nivolumab: a\u00a0prospective cohort study. J Thorac Oncol. 2017, 12:1798-805. 10.1016\/j.jtho.2017.08.022","journal-title":"J Thorac Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/62887-long-term-survival-with-pembrolizumab-re-administration-after-pseudo-progression-with-immune-related-interstitial-lung-disease-in-a-patient-with-non-small-cell-lung-cancer","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:31:41Z","timestamp":1707507101000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/62887-long-term-survival-with-pembrolizumab-re-administration-after-pseudo-progression-with-immune-related-interstitial-lung-disease-in-a-patient-with-non-small-cell-lung-cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,4]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.16177","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7,4]]}}}